Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CFO Sells $196,132.21 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CFO Matt Abernethy sold 1,283 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $152.87, for a total value of $196,132.21. Following the transaction, the chief financial officer now directly owns 32,681 shares in the company, valued at approximately $4,995,944.47. This trade represents a 3.78 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Neurocrine Biosciences Trading Up 1.5 %

NASDAQ NBIX traded up $2.32 during trading hours on Tuesday, hitting $152.42. The company’s stock had a trading volume of 814,308 shares, compared to its average volume of 950,096. Neurocrine Biosciences, Inc. has a 52 week low of $110.95 and a 52 week high of $157.98. The company has a market capitalization of $15.43 billion, a PE ratio of 40.86 and a beta of 0.33. The company’s 50-day simple moving average is $137.92 and its two-hundred day simple moving average is $131.51.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on NBIX. BMO Capital Markets lowered their price target on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research report on Thursday, October 17th. HC Wainwright reissued a “buy” rating and set a $190.00 price target on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Raymond James reissued an “outperform” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a research report on Friday, December 20th. Finally, UBS Group upped their target price on Neurocrine Biosciences from $162.00 to $176.00 and gave the company a “buy” rating in a research report on Thursday, January 30th. Five analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $166.85.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of hedge funds have recently modified their holdings of the stock. Golden State Wealth Management LLC purchased a new position in Neurocrine Biosciences in the 4th quarter valued at approximately $25,000. Brooklyn Investment Group grew its position in Neurocrine Biosciences by 99.1% in the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock worth $32,000 after acquiring an additional 115 shares in the last quarter. Blue Trust Inc. lifted its stake in Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after purchasing an additional 220 shares during the last quarter. R Squared Ltd bought a new stake in Neurocrine Biosciences in the fourth quarter worth $61,000. Finally, UMB Bank n.a. lifted its stake in Neurocrine Biosciences by 211.6% in the fourth quarter. UMB Bank n.a. now owns 455 shares of the company’s stock worth $62,000 after purchasing an additional 309 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.